Success Metrics

Clinical Success Rate

25.0%

Based on 2 completed trials

Completion Rate

25%(2/8)

Active Trials

0(0%)

Results Posted

150%(3 trials)

Terminated

6(67%)

Phase Distribution

Ph phase_2

33%

Ph phase_3

11%

Ph phase_1

56%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

5(55.6%)

Phase 2Efficacy & side effects

3(33.3%)

Phase 3Large-scale testing

1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

22.2%

2 of 9 finished

Non-Completion Rate

77.8%

7 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(7)

Detailed Status

Terminated6

Completed2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

25.0%

Most Advanced

Phase 3

Trials by Phase

Phase 15 (55.6%)

Phase 23 (33.3%)

Phase 31 (11.1%)

Trials by Status

withdrawn111%

completed222%

terminated667%

Recent Activity

0 active trials

Showing 5 of 9

terminatedphase_1

FOLFIRINOX + NIS793 in Pancreatic Cancer

NCT05417386

terminatedphase_2

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

NCT04390763

terminatedphase_1

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

NCT04810611

terminatedphase_1

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

NCT04097821

terminatedphase_2

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

NCT04952753

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT05417386Phase 1

FOLFIRINOX + NIS793 in Pancreatic Cancer

Terminated

NCT04390763Phase 2

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Terminated

NCT04810611Phase 1

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated

NCT04097821Phase 1

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients

Terminated

NCT04952753Phase 2

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

Terminated

NCT04935359Phase 3

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

Completed

NCT05546411Phase 2

A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer

Terminated

NCT02947165Phase 1

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Completed

NCT04283526Phase 1

Study of Select Combinations in Adults With Myelofibrosis

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9